Iovance Submits Marketing Authorization Application To European Medicines Agency For Lifileucel

(RTTNews) - Iovance Biotherapeutics (IOVA) submitted a marketing authorization application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The MAA submission is supported by positive clinical data from the C-144-01 clinical trial in patients with advanced post-anti-PD1 melanoma.

The company noted that, if approved, lifileucel will be the first and only approved therapy in this treatment setting in all European Union member states.

For More Such Health News, visit rttnews.com.